Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$116 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.8
Industry P/E
--
EV/EBITDA
-3.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
46,671,500
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
| 35.9 | 35.1 | -20.1 | -33.8 | -4.0 | -- | -- |
|
BSE Sensex*
| 3.5 | 1.9 | 7.5 | 9.5 | 14.2 | 21.2 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
Vigil Neuroscience (VIGL)
| -49.4 | -73.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 |
|
BSE Sensex
| 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vigil Neuroscience (VIGL)
|
2.3 | 115.8 | 0.0 | -86.7 | -- | -112.9 | -- | 1.8 |
| 46.7 | 7,725.5 | 1,208.8 | 131.7 | 13.4 | 6.3 | 59.4 | 3.8 | |
| 101.5 | 6,652.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 19.4 | |
| 134.3 | 7,049.6 | 4,022.6 | -31.6 | 3.7 | -1.1 | 618.4 | 2.2 | |
| 56.9 | 10,905.2 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.5 | |
| 43.7 | 12,097.3 | 2,298.9 | 643.6 | 27.3 | 29.2 | 20.3 | 5.7 | |
| 53.9 | 6,586.2 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14.2 | 13.6 | |
| 295.8 | 8,785.2 | 2,156.6 | 416.4 | 15.6 | 56.5 | 23.3 | 14.8 | |
| 25.8 | 10,824.9 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 120.6 | 12,168.8 | 2,412.6 | 305.8 | 20.5 | 11.6 | 41.7 | 4.8 |
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States.... The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. It also developing VG-3927, an orally available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts. Address: 100 Forge Road, Watertown, MA, United States, 02472 Read more
President, CEO & Director
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
President, CEO & Director
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
Headquarters
Watertown, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Vigil Neuroscience Inc (VIGL) stood at $ 138 Mln as on 31-Mar-25
The share price of Vigil Neuroscience Inc (VIGL) is $2.31 (NASDAQ) as of 21-May-2025 16:02 EDT. Vigil Neuroscience Inc (VIGL) has given a return of -3.99% in the last 3 years.
Vigil Neuroscience Inc (VIGL) has a market capitalisation of $ 116 Mln as on 21-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Vigil Neuroscience Inc (VIGL) is 1.78 times as on 21-May-2025, a 22% discount to its peers’ median range of 2.28 times.
Since, TTM earnings of Vigil Neuroscience Inc (VIGL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Vigil Neuroscience Inc (VIGL) and enter the required number of quantities and click on buy to purchase the shares of Vigil Neuroscience Inc (VIGL).
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. It also developing VG-3927, an orally available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts. Address: 100 Forge Road, Watertown, MA, United States, 02472
The CEO & director of Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.. is Vigil Neuroscience Inc (VIGL), and CFO & Sr. VP is Dr. Ivana Magovcevic-Liebisch J.D., Ph.D..
There is no promoter pledging in Vigil Neuroscience Inc (VIGL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,230
|
|
|
1,176
|
|
|
1,035
|
|
|
929
|
|
|
838
|
|
|
820
|
|
|
750
|
|
|
682
|
|
|
630
|
| Vigil Neuroscience Inc. (VIGL) | Ratios |
|---|---|
|
Return on equity(%)
|
-112.87
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Vigil Neuroscience Inc (VIGL) was $0 Mln.
$-0.17
(
